Last reviewed · How we verify
Prevention of Posterior Synechiae — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Sudafed PE | phenylephrine | Generic (multiple manufacturers) | Alpha-1 adrenergic agonist (decongestant/vasopressor) | Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor | 1976-01-01 | |
| Phenergan Vc W/ Codeine | PHENYLEPHRINE BITARTRATE | ANI Pharmaceuticals | Nonsteroidal Anti-inflammatory Drug [EPC] | Alpha-1B adrenergic receptor | 1952-01-01 | |
| scopolamin | scopolamin | University Hospital, Angers | Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- ANI Pharmaceuticals · 1 drug in Prevention of Posterior Synechiae
- Generic (multiple manufacturers) · 1 drug in Prevention of Posterior Synechiae
- University Hospital, Angers · 1 drug in Prevention of Posterior Synechiae
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prevention of Posterior Synechiae:
- Prevention of Posterior Synechiae treatment updates — RSS
- Prevention of Posterior Synechiae treatment updates — Atom
- Prevention of Posterior Synechiae treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prevention of Posterior Synechiae — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-posterior-synechiae. Accessed 2026-06-10.
Related
- Prevention of Posterior Synechiae full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing